NASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis $136.71 -2.33 (-1.68%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Repligen Stock (NASDAQ:RGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Repligen alerts:Sign Up Key Stats Today's Range$135.98▼$142.8950-Day Range$136.39▼$167.3552-Week Range$110.45▼$211.13Volume596,372 shsAverage Volume674,072 shsMarket Capitalization$7.66 billionP/E Ratio546.86Dividend YieldN/APrice Target$190.25Consensus RatingModerate Buy Company OverviewRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More… Next opportunity for crypto millions (Ad)October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…Go here to discover the coin that could define this historic bull run with gains kicking off this mo Repligen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks98th Percentile Overall ScoreRGEN MarketRank™: Repligen scored higher than 98% of companies evaluated by MarketBeat, and ranked 24th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRepligen has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Repligen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth34.48% Earnings GrowthEarnings for Repligen are expected to grow by 34.48% in the coming year, from $1.45 to $1.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 546.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 118.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 546.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 109.12.Price to Earnings Growth RatioRepligen has a PEG Ratio of 4.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Repligen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.52% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Repligen has recently decreased by 3.21%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.33 Percentage of Shares Shorted7.52% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Repligen has recently decreased by 3.21%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment1.27 News SentimentRepligen has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Repligen this week, compared to 6 articles on an average week.MarketBeat Follows1 people have added Repligen to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,965,622.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repligen's insider trading history. Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Stock News HeadlinesInsider Selling: Repligen Co. (NASDAQ:RGEN) Director Sells 22,191 Shares of StockSeptember 13, 2024 | insidertrades.comMosaic ImmunoEngineering (OTCMKTS:CPMV) & Repligen (NASDAQ:RGEN) Critical ComparisonOctober 3 at 2:11 AM | americanbankingnews.comNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… October 6, 2024 | Crypto 101 Media (Ad)Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)September 27, 2024 | markets.businessinsider.comRoyal Bank of Canada Reiterates "Outperform" Rating for Repligen (NASDAQ:RGEN)September 27, 2024 | americanbankingnews.comVoya Large Cap Growth Strategy Q2 2024 CommentarySeptember 26, 2024 | seekingalpha.comRepligen Opens Training & Innovation Center to Elevate Customer ExperienceSeptember 24, 2024 | globenewswire.comRGEN Jan 2025 80.000 putSeptember 22, 2024 | ca.finance.yahoo.comSee More Headlines RGEN Stock Analysis - Frequently Asked Questions How have RGEN shares performed this year? Repligen's stock was trading at $179.80 at the start of the year. Since then, RGEN shares have decreased by 24.0% and is now trading at $136.71. View the best growth stocks for 2024 here. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) posted its earnings results on Tuesday, July, 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen's revenue for the quarter was down 3.2% compared to the same quarter last year. Does Repligen have any subsidiaries? Repligen subsidiaries include these companies: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and more. Who are Repligen's major shareholders? Repligen's top institutional investors include Handelsbanken Fonder AB (0.02%), SG Americas Securities LLC (0.01%) and Park Avenue Securities LLC (0.01%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus, Manner Carrie Eglinton, Nicolas Barthelemy and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU) and Walt Disney (DIS). Company Calendar Last Earnings7/30/2024Today10/06/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,783Year Founded1981Price Target and Rating Average Stock Price Target$190.25 High Stock Price Target$220.00 Low Stock Price Target$155.00 Potential Upside/Downside+39.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.25 Trailing P/E Ratio546.86 Forward P/E Ratio94.28 P/E Growth4.24Net Income$41.58 million Net Margins-0.32% Pretax Margin1.69% Return on Equity3.36% Return on Assets2.41% Debt Debt-to-Equity Ratio0.26 Current Ratio6.65 Quick Ratio5.56 Sales & Book Value Annual Sales$638.76 million Price / Sales11.99 Cash Flow$2.89 per share Price / Cash Flow47.34 Book Value$35.31 per share Price / Book3.87Miscellaneous Outstanding Shares56,010,000Free Float55,205,000Market Cap$7.66 billion OptionableOptionable Beta0.95 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RGEN) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.